Amneal Pharmaceuticals (AMRX) Enterprise Value (2018 - 2026)

Amneal Pharmaceuticals has reported Enterprise Value for 9 years, with the latest figure at $5.5 billion in Q2 2026.

• On a quarterly basis, Enterprise Value rose 116.33% year-over-year to $5.5 billion in Q2 2026; TTM through Jun 2026 was $5.5 billion, a 116.33% increase from a year earlier, with the FY2025 full-year figure at $3.8 billion, up 56.04% from the prior year.
• Enterprise Value was $5.5 billion for Q2 2026 at Amneal Pharmaceuticals, up from $3.9 billion in the prior quarter.
• The five-year high for Enterprise Value was $5.5 billion in Q2 2026, with the low at $307.4 million in Q1 2023.
• Average Enterprise Value over 5 years is $2.1 billion, with a median of $1.9 billion recorded in 2024.
• The sharpest annual moves came in 2023 and 2024: Enterprise Value tumbled 71.24% in 2023, then surged 508.56% in 2024.
• Over 5 years, Enterprise Value stood at $603.2 million in 2022, then jumped by 200.09% to $1.8 billion in 2023, then surged by 33.11% to $2.4 billion in 2024, then soared by 56.04% to $3.8 billion in 2025, then jumped by 45.88% to $5.5 billion in 2026.
• The last three Enterprise Value figures came in at $5.5 billion (Q2 2026), $3.9 billion (Q1 2026), and $3.8 billion (Q4 2025), per Business Quant data.